CA
NZ
UK
AU
IND
US
Fox Corp (NASDAQ: FOXA) has struck a definitive agreement to acquire Roku (NASDAQ: ROKU) in a $22 billion transaction, signaling a major shift in the media landscape.
US stocks rallied Monday as a preliminary US-Iran agreement to reopen the Strait of Hormuz eased inflation concerns and pushed oil prices lower. The S&P 500, Dow and Nasdaq posted strong gains, led by tech and fuel-sensitive stocks, while SpaceX extended its post-IPO surge …
Sinovac Biotech Ltd (NASDAQ: SVA) has reported its regulatory standing with the recent submission of a Form 6-K to the U.S.
Tiziana Life Sciences (NASDAQ: TLSA), a biopharmaceutical company developing innovative therapies, has drawn attention following a recent share purchase by its chairman and founder, Gabriele Cerrone.
Cuprina Holdings (NASDAQ: CUPR) has achieved a pivotal milestone with the U.S. Food and Drug Administration's clearance of its MEDIFLY Maggots. This decision, announced on June 15, 2026, opens avenues for the application of live maggots in the treatment of chronic wounds, tapping into …
SANUWAVE Health, Inc. (OTC: SNWV) has filed an 8-K report with the U.S. Securities and Exchange Commission detailing a submission for security holder votes. This step may indicate expected changes in corporate direction or governance, attracting scrutiny from investors and analysts alike.
The company secured shareholder backing for a series of corporate measures at its 2026 annual general meeting, including a reverse stock split.
A developer of Nasarix, a nasal drug delivery technology, has initiated a human study designed to evaluate the platform’s residence time in the nasal cavity. The trial marks a pivotal step in the company’s efforts to strengthen its regulatory strategy ahead of potential FDA …
On June 15, 2026, NewcelX (NASDAQ: NCEL) announced the publication of a peer-reviewed study examining its stem cell research. The company, incorporated under Swiss law, has been advancing its work in this area, and the study provides new insights into its ongoing efforts.
A diagnostics company supported by OrbiMed has announced plans to raise $250 million through a private placement of convertible senior notes. The notes, set to mature in 2031, will be offered to qualified institutional buyers under Rule 144A of the Securities Act of 1933. …
Please wait processing your request...